<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00335868</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000486219</org_study_id>
    <secondary_id>UCLA-0601009-01</secondary_id>
    <secondary_id>NERVIANO-AURA-6202-005</secondary_id>
    <nct_id>NCT00335868</nct_id>
  </id_info>
  <brief_title>PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy</brief_title>
  <official_title>A Pilot Phase II Study of PHA-739358 in Patients With Chronic Myeloid Leukemia Relapsing on Gleevec or c-ABL Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: PHA-739358 may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well PHA-739358 works in treating patients with&#xD;
      chronic myelogenous leukemia that relapsed after imatinib mesylate or c-ABL therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Explore the clinical efficacy of PHA-739358, in terms of hematological response lasting&#xD;
           ≥ 4 weeks, in patients with chronic myelogenous leukemia that relapsed after imatinib&#xD;
           mesylate or c-ABL therapy.&#xD;
&#xD;
        -  Explore the safety profile of this drug in these patients.&#xD;
&#xD;
        -  Explore the pharmacokinetic profile of this drug and its N-oxide metabolite PHA-816359&#xD;
           in plasma.&#xD;
&#xD;
        -  Explore the modulation of histone H3 and CRKL phosphorylation after PHA-739358&#xD;
           administration.&#xD;
&#xD;
        -  Explore the relationship between plasma drug levels and the modulation of histone H3 and&#xD;
           CRKL phosphorylation.&#xD;
&#xD;
        -  Explore the clinical efficacy of this drug, in terms of cytogenetic response in bone&#xD;
           marrow.&#xD;
&#xD;
        -  Explore response depending on status of T315I mutation in BCR-ABL kinase.&#xD;
&#xD;
      OUTLINE: This is a pilot, open-label, multicenter study.&#xD;
&#xD;
      Patients receive PHA-739358 IV over 6 hours on days 1, 8, and 15. Treatment repeats every 28&#xD;
      days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients&#xD;
      benefitting from treatment may receive additional courses at the discretion of the&#xD;
      investigator.&#xD;
&#xD;
      Patients undergo blood collection and bone marrow biopsies periodically for pharmacologic and&#xD;
      biomarker correlative studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 16 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2007</start_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antileukemic response in terms of complete hematological response, no evidence of leukemia, or return to chronic phase</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall safety profile of PHA-739358 by type, severity, timing, and relatedness of adverse events and laboratory abnormalities</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of this drug and its N-oxide metabolite PHA-816359 by measuring their plasma concentration at different times after dosing</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in histone H3 and CRKL phosphorylation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between changes in degree of histone H3 and CRKL phosphorylation and concurrent PHA-739358 concentrations and/or hematological response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete, partial, or minor cytogenetic response in bone marrow</measure>
  </primary_outcome>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>danusertib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of chronic myelogenous leukemia confirmed by bone marrow biopsy&#xD;
&#xD;
               -  Chronic, accelerated, or blastic phase disease&#xD;
&#xD;
          -  May have T315I mutation in BCR-ABL kinase&#xD;
&#xD;
          -  Relapsed after prior imatinib mesylate or c-ABL therapy&#xD;
&#xD;
          -  No CNS leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Blood pressure ≤ 140/90 mm Hg (with or without hypertension treatment for ≥ 1 week)&#xD;
&#xD;
          -  Transaminases ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  No known history of HIV infection&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No grade 3 or 4 bleeding&#xD;
&#xD;
          -  LVEF ≥ 45% by MUGA or ≥ 40% by transthoracic echocardiography&#xD;
&#xD;
          -  No medical or psychiatric condition or laboratory abnormalities that would limit study&#xD;
             compliance or increase risk during study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 90 (female) or 180&#xD;
             (male) days after completion of study treatment&#xD;
&#xD;
          -  No significant cardiovascular disease (i.e., uncontrolled arrhythmias or unstable&#xD;
             angina) within the past 6 months&#xD;
&#xD;
          -  No major thromboembolic event within the past 6 months, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Stroke&#xD;
&#xD;
               -  Transient ischemic attack&#xD;
&#xD;
               -  Pulmonary embolism&#xD;
&#xD;
               -  Noncatheter-related deep-vein thrombosis&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Recovered from all acute toxic effects (excluding alopecia) of prior therapy&#xD;
&#xD;
          -  More than 2 weeks since prior chemoimmunotherapy&#xD;
&#xD;
               -  Hydroxyurea must be discontinued 1 day prior to study therapy&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
          -  No other concurrent approved or investigational anticancer treatment, including&#xD;
             chemotherapy, biologic response modifiers, hormones, or immunotherapy&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No concurrent participation in another treatment clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Paquette, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>June 8, 2006</study_first_submitted>
  <study_first_submitted_qc>June 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2006</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <responsible_party>
    <name_title>Ronald Paquette</name_title>
    <organization>Jonsson Comprehensive Cancer Center at UCLA</organization>
  </responsible_party>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

